Avid Bioservices Inc (CDMO)

[north40000]

CP, u seem to contradict yourself here:

"My POST certainly did not IMPLY it is sure there will be a Reverse Split, if that is what you understood then I have conveyed the wrong sentiment. Just the last days I lowered the chance of a RS from my 50/50 to better then 50/50."

I am not Flemish, but I understand the above to say you think we have a greater[better] chance of RS than you previously did. Ambiguous?

What do we make of AZN news from ESMO, per Hutschi's earlier post...I continue to see NO mention of Bavi in combo with Durvalumab?:



"At ESMO 2016 Congress, AstraZeneca will present a range of new and updated data from its Immuno-Oncology programme, including:

· Updated results from the Phase I/II trial (Study 1108) of durvalumab in patients with NSCLC (Abstract # 1216PD), and HNSCC (Abstract # 2085 - oral presentation).

· Early data from a Phase Ib trial (SCORES) of durvalumab combined with AZD9150 (a STAT3 inhibitor) or AZD5069 (a CXCR2 antagonist) in patients with HNSCC and advanced solid malignancies (Abstract # 1049PD)."

Still planning ? No pre-clinicals yet? or muffled data link like their recently completed, but redacted, trial results here that I posted yesterday on the AZN board:

"Who blacked out portions of this link? Why were they blacked out?

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&&studyid=4425&&filename=OMA_EPA_009_CSR.pdf "